Aggressive skin cancer driven by mitochondrial processes –existing drugs offer promising treatment path
Peer-Reviewed Publication
Updates every hour. Last Updated: 6-Nov-2025 17:11 ET (6-Nov-2025 22:11 GMT/UTC)
A new study led by researchers at Lund University in Sweden, reveals that melanoma, the deadliest form of skin cancer, can in some cases be driven by mitochondrial processes, which can be effectively targeted using existing drugs. In preclinical laboratory experiments with melanoma cell cultures, researchers successfully eliminated cancer cells by using antibiotics and inhibitors of mitochondrial energy production, highlighting a potential therapeutic breakthrough.
– Despite these challenging times, two universities remain steadfast in the commitment to curing one of the world’s most deadly diseases. Recognizing the power of education and research in preventing, treating, and advancing life-saving treatments, the Hebrew University of Jerusalem and Georgetown University have established a joint initiative on cancer to amplify innovation, discovery, and action to end the disease.
Chemists have discovered for the first time a unique way to control and modify a type of compound widely used in medicines, including a drug used to treat breast cancer.
Chronic inflammation occurs when the immune system is stuck in attack-mode, sending cell after cell to defend and repair the body for months or even years. Diseases associated with chronic inflammation, like arthritis or cancer or autoimmune disorders, weigh heavily on human health—and experts anticipate their incidence is on the rise. A new study by investigators from Mass General Brigham identified a protein called WSTF that could be targeted to block chronic inflammation. Crucially, this strategy would not interfere with acute inflammation, allowing the immune system to continue responding appropriately to short-term threats, such as viral or bacterial infection. Results are published in Nature.
A team led by researchers at Baylor College of Medicine and Washington University School of Medicine has shed light on the process that drives Barrett’s esophagus formation. This condition affects the lining of the esophagus – the tube that carries food from the mouth to the stomach – and increases the risk of developing esophageal adenocarcinoma, a serious and often deadly cancer.
The study reveals that two important genes involved in guiing and maintaining the identity of the esophagus and intestine, SOX2 and CDX2, are altered in Barrett’s esophagus. The findings not only deepen our understanding of how the disease develops but also open the door to new ways of identifying people at risk and potentially preventing the condition from progressing to cancer.